Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report

Basit Öğe Kaydı
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorKars, Taha U.
dc.contributor.authorDikici, Hatice Z.
dc.contributor.authorYilmaz, Pinar D.
dc.contributor.authorDemircioglu, Sinan
dc.contributor.authorCeneli, Ozcan
dc.date.accessioned2024-02-23T14:27:02Z
dc.date.available2024-02-23T14:27:02Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIntroduction Cardiac involvement in diffuse large B-cell lymphoma is a rare entity in non-Hodgkin lymphomas. Symptoms are usually related to heart failure. Patients who are severely symptomatic due to cardiac mass could be considered treatment as soon as possible. In this report, we present a patient diagnosed with diffuse large B-cell lymphoma with cardiac involvement. Case Report A 61-year-old female patient was admitted to our unit with gastric biopsy diffuse large B-cell lymphoma. Computerized tomography of the chest and positron emission tomography/computed tomography demonstrated a neoplastic mass in the intra-atrial septum extended to inferior vena cava (5 x 4 cm in size and standardized uptake value maximum 24.6). She was in stage III and in the high-risk group. Because of pronounced heart failure findings associated with the mass-specific chemotherapy was planned early. Management & Outcome Although a fraction of ejection was 60% by echocardiography before the treatment, she had a cardiac risk for doxorubicin due to being over 60 years old and hypertension. Complete remission was achieved after three cycles of rituximab-cyclophosphamide-doxorubicin-vincristine and methylprednisolone protocol including doxorubicin. Treatment was completed with six cycles and she was followed up for three months. Discussion Because of the cardiotoxicity of doxorubicin-based protocols, patients should be evaluated according to cardiac functions before and during the chemotherapy.en_US
dc.identifier.doi10.1177/10781552211035120
dc.identifier.endpage452en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue2en_US
dc.identifier.pmid34549658en_US
dc.identifier.scopus2-s2.0-85115603281en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.1177/10781552211035120
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14427
dc.identifier.volume28en_US
dc.identifier.wosWOS:000702391800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnthracyclineen_US
dc.subjectCardiotoxicityen_US
dc.subjectLymphomaen_US
dc.subjectNon-Hodgkinen_US
dc.titleTreatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu